Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of E2730 in Healthy Participants
NCT03054194Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2730 in epilepsy (6 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Number of participants with any serious adverse event and number of participants with any non-serious adverse event, Number of participants with an abnormal, clinically significant hematology parameter value at Day 10 and 18 more. Started Jan 2017; status: completed.
02
Drugs
E2730
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03054194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054194.